Hallucinogens, Serotonin and Obsessive-Compulsive Disorder

Delgado and Moreno frame obsessive-compulsive disorder (OCD) as a condition in which the serotonin (5-HT) neurotransmitter system has long been implicated, and note that blockade of 5-HT reuptake is a key early neurobiological action of anti-obsessional drugs. They highlight a clinical gap: although potent 5-HT reuptake inhibitors (SSRIs and related agents) are effective for many patients, therapeutic improvement is typically delayed by several weeks and complete recovery is uncommon. This article sets out to review clinical and preclinical data linking hallucinogenic drugs to serotonin receptor activity and to examine evidence that activation of 5-HT2 (particularly 5-HT2A and 5-HT2C) and possibly 5-HT1A receptors might produce acute or longer-lasting reductions in OCD symptoms. The authors aim to summarise pharmacology, reported clinical effects in probable OCD cases, and safety considerations, and to argue that controlled trials of potent 5-HT2 agonists in OCD are warranted.

The extracted text does not describe a formal systematic search strategy, inclusion/exclusion criteria, or quantitative meta-analytic methods. Instead, the paper is presented as a narrative review synthesising multiple lines of evidence. Evidence sources assembled by the authors include case reports and anecdotal clinical observations of hallucinogen use in people with obsessive-compulsive or related disorders, controlled clinical trial data on standard OCD treatments (notably trials of fluvoxamine and other potent 5-HT reuptake inhibitors), preclinical pharmacology studies (receptor binding, electrophysiology, tolerance and down-regulation experiments), and surveys or follow-up studies addressing adverse events associated with hallucinogens. No explicit methods for literature identification, study selection, or risk-of-bias assessment are reported in the extracted text.

Clinical case reports and uncontrolled observations: The review summarises several single-case reports and anecdotal series suggesting that some individuals with "obsessional neurosis" (older terminology for OCD) experienced marked and sometimes durable symptom relief after exposure to hallucinogens. Examples include a 35-year-old man with violent sexual obsessions who reportedly had dramatic and lasting improvement after two doses of LSD, and a 30-year-old man with severe contamination obsessions and washing compulsions treated with an initial 60 µg then 100 µg LSD weekly for 56 treatments over 15 months, who progressively reduced rituals by about 50% and eventually became asymptomatic over the subsequent three years. Other reports describe short-term remissions lasting hours (for example a 17-year-old who had transient remission for four to five hours after LSD) and cases in which chronic or repeated use produced remission that persisted for months after cessation. A single case of body dysmorphic disorder is noted where psilocybin produced relief lasting only the duration of the acute experience. Pharmacology: The authors report that a substantial body of data links the psychedelic effects of classical hallucinogens (LSD, psilocybin, mescaline) to agonist activity at 5-HT2 receptors, particularly the 5-HT2A subtype, and also 5-HT2C. In vitro binding potency at these receptors correlates with human hallucinogenic potency. Mechanistic hypotheses described include 5-HT2-mediated modulation of locus coeruleus noradrenergic neurons (reducing spontaneous firing but enhancing stimulus-driven activation) and activation of a subset of cortical interneurons, which together could amplify and distort sensory input. The authors suggest that such perceptual and cognitive changes might alter how stimuli associated with obsessions and compulsions are experienced, or that direct pharmacological effects at 5-HT2 receptors could underlie acute symptom reduction. Neurobiology and existing treatments for OCD: OCD prevalence is cited as about 2% to 3% in the general population, with common comorbidities (lifetime prevalence of depression 67% and phobias 25% in OCD patients). Mean age of onset is around 20 years, with most developing the disorder by age 25. Clinical trial data summarised include a 10-week, placebo-controlled, double-blind study of fluvoxamine in 160 patients (100 to 300 mg/day), in which fluvoxamine was significantly more effective than placebo and produced higher responder rates. The authors emphasise that all currently effective pharmacological treatments for OCD share potent inhibition of 5-HT reuptake, but note that clinical responses are often partial (satisfactory responses may approach only 50% of patients) and commonly require 4 to 8 weeks or longer to emerge; symptom reductions are often in the range of 30% to 50% among responders. Mechanistic studies and adjunctive treatments: Experimental work addressing the delayed time course of SSRI benefit implicates 5-HT1A autoreceptor feedback and its desensitisation over weeks as a mechanism for later increases in 5-HT neurotransmission. Tryptophan depletion paradigms produced different effects in depression versus OCD: in fluvoxamine-treated depressed patients depletion caused an acute return of depressive symptoms, whereas in a similar test with fluvoxamine-treated OCD patients there was no return of OCD symptoms (though prior depression recurred in those with comorbid depression). These findings are interpreted as supporting adaptive postsynaptic changes rather than a simple dependence on elevated synaptic 5-HT. Combined pharmacotherapies have produced mixed findings: addition of agents with 5-HT2 antagonist properties (risperidone, trazodone, olanzapine, clozapine) has in many cases been used without exacerbating OCD and sometimes with apparent synergistic benefit, whereas m-chlorophenylpiperazine (m-CPP), a 5-HT2C agonist, may exacerbate symptoms in some patients. The literature is heterogeneous and not definitive. Tolerance, receptor regulation and cross-tolerance: Repeated daily use of classical hallucinogens leads to rapid tolerance, with marked diminution of effects by the third day. Tolerance correlates with down-regulation of 5-HT2 receptors in preclinical studies. Potent 5-HT reuptake inhibitors inconsistently reduce 5-HT2 receptor binding but more consistently blunt 5-HT2-mediated behavioural responses in humans, and tricyclic antidepressants may enhance hallucinogen effects; taken together, these data suggest overlapping adaptive mechanisms and possible cross-tolerance between SSRIs and hallucinogens. Adverse effects and safety: The authors classify adverse events into five categories: acute dysphoric or psychotic reactions ("bad trips"), flashbacks, long-term psychosis or schizoaffective conditions, long-term personality change, and post-hallucinogen perceptual disorder. Typical acute effects include intense perceptual distortions, mood swings, autonomic effects, and anxiety or panic; these usually begin 20 to 30 minutes after ingestion and last hours. Reported rates vary and are limited by uncontrolled data: flashback rates in some samples were around 5% to 12% depending on exposure and setting; an estimated incidence of LSD-related psychosis in experimental subjects was about 0.8 per 1,000; follow-up studies of medical LSD use found little evidence of measurable long-term effects in group analyses. The post-hallucinogen perceptual disorder (chronic visual disturbances) is described as occurring in some individuals and sometimes associated with distress; rare cases of suicide or violent behaviour temporally associated with hallucinogen use are noted but difficult to interpret because of confounding factors. Overall, the authors stress that precise risk rates are unknown because of the paucity of controlled safety data.

Delgado and Moreno interpret the assembled evidence as supporting the hypothesis that activation of 5-HT2 receptors by hallucinogens may produce acute—and in a few reported cases, longer-lasting—reductions in OCD symptoms. They acknowledge that it remains unclear whether therapeutic benefit, when observed, derives from the immediate physiological consequences of 5-HT2 receptor activation or from downstream adaptive changes such as receptor desensitisation or other plasticity in 5-HT-innervated circuits. The authors position these observations within existing knowledge about OCD neurobiology and pharmacotherapy: SSRIs are effective but slow, and adaptive postsynaptic changes may be necessary for symptom improvement, which suggests a potential rationale for exploring agents that directly activate relevant 5-HT receptor subtypes. At the same time, they emphasise the limitations of the literature—most human data on hallucinogens in OCD are case reports or uncontrolled observations, preclinical mechanisms are incompletely understood, and findings across studies are mixed. Safety concerns represent a major constraint: hallucinogens can produce frightening acute reactions, carry uncertain risks of persistent perceptual disturbance or psychosis, and may pose greater risks in people with pre-existing psychiatric illness. Regulatory restrictions on human research with hallucinogens have further limited the ability to determine precise benefit–risk profiles. Given these uncertainties, the authors conclude that carefully controlled clinical investigation is essential. They suggest that understanding the mechanisms underlying any rapid anti-obsessional effects could inform the development of faster-acting and more effective treatments, and they advocate for controlled trials of potent 5-HT2 agonists in people with OCD, undertaken with attention to safety and patient selection.

The authors conclude that available clinical and preclinical data are consistent with the possibility that activation of 5-HT2 receptors by hallucinogens can lead to acute therapeutic effects in some patients with OCD, and that receptor desensitisation or interactions with other 5-HT receptor subtypes might account for more sustained benefit. They reiterate that hallucinogens carry real risks, that precise adverse-event rates are unknown, and that people with pre-existing psychiatric disorders may be at higher risk. Finally, Delgado and Moreno argue that, because OCD can be severely disabling and current treatments are suboptimal for many patients, carefully controlled clinical trials of selective 5-HT2 agonists are warranted and may yield important advances for patients who otherwise remain treatment-refractory.